- Home
- AAL vs ROIV Comparison
AAL vs ROIV Comparison
Compare AAL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAL
- ROIV
- Stock Information
- Founded
- AAL 1930
- ROIV 2014
- Country
- AAL United States
- ROIV United Kingdom
- Employees
- AAL N/A
- ROIV N/A
- Industry
- AAL Air Freight/Delivery Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- AAL Consumer Discretionary
- ROIV Health Care
- Exchange
- AAL Nasdaq
- ROIV Nasdaq
- Market Cap
- AAL 6.9B
- ROIV 8.4B
- IPO Year
- AAL N/A
- ROIV N/A
- Fundamental
- Price
- AAL $11.86
- ROIV $10.79
- Analyst Decision
- AAL Hold
- ROIV Buy
- Analyst Count
- AAL 15
- ROIV 4
- Target Price
- AAL $13.87
- ROIV $17.50
- AVG Volume (30 Days)
- AAL 65.3M
- ROIV 5.9M
- Earning Date
- AAL 04-24-2025
- ROIV 05-29-2025
- Dividend Yield
- AAL N/A
- ROIV N/A
- EPS Growth
- AAL 35.09
- ROIV N/A
- EPS
- AAL 1.02
- ROIV N/A
- Revenue
- AAL $54,192,000,000.00
- ROIV $122,585,000.00
- Revenue This Year
- AAL $1.73
- ROIV N/A
- Revenue Next Year
- AAL $5.94
- ROIV N/A
- P/E Ratio
- AAL $11.64
- ROIV N/A
- Revenue Growth
- AAL 1.92
- ROIV 140.04
- 52 Week Low
- AAL $8.50
- ROIV $8.73
- 52 Week High
- AAL $19.10
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- AAL 62.56
- ROIV 50.06
- Support Level
- AAL $11.47
- ROIV $10.58
- Resistance Level
- AAL $12.45
- ROIV $11.77
- Average True Range (ATR)
- AAL 0.42
- ROIV 0.34
- MACD
- AAL 0.25
- ROIV -0.07
- Stochastic Oscillator
- AAL 80.13
- ROIV 17.65
About AAL American Airlines Group Inc.
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of US legacy carriers.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.